Life Sciences Virtual Investor Forum - Nasus Pharma Ltd. (NYSE: NSRX) скачать в хорошем качестве

Life Sciences Virtual Investor Forum - Nasus Pharma Ltd. (NYSE: NSRX)

This video is part of the ‪@OTCMarketsGroup‬ Life Sciences Virtual Investor Forum by Virtual Investor Conferences, a ‪@b2idigital‬ Featured Conference, held on March 11th & 12th, 2026. Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn. Watch the full Nasus Pharma Ltd. (NYSE: NSRX) presentation and request meetings with management at: https://www.virtualinvestorconference... Any questions or need assistance setting up meetings, contact Joseph Azizo, Capital Markets Associate at B2i Digital: joseph@b2idigital.com